Abstract
Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, hereditary autoinflammatory condition, characterized by recurrent inflammatory episodes. There is no proven treatment for HIDS, but various drugs including, non-steroidal anti-inflammatory drugs, colchicine, steroids, statins and thalidomide have all been tried. Recently, some patients have demonstrated a good clinical response to either etanercept or anakinra. We report a case of a 10-year-old girl who experienced prolonged and severe inflammatory attacks, when she was treated with etanercept, and later with anakinra.
MeSH terms
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use
-
Child
-
Etanercept
-
Female
-
Fever / chemically induced*
-
Fever / physiopathology
-
Humans
-
Immunoglobulin G / adverse effects*
-
Immunoglobulin G / therapeutic use*
-
Interleukin 1 Receptor Antagonist Protein / adverse effects*
-
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
-
Mevalonate Kinase Deficiency / drug therapy*
-
Mevalonate Kinase Deficiency / physiopathology
-
Receptors, Tumor Necrosis Factor / therapeutic use*
-
Time Factors
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Antirheumatic Agents
-
Immunoglobulin G
-
Interleukin 1 Receptor Antagonist Protein
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Etanercept